Human adenovirus e serotype 4 strain cl-68578 antigen

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Human adenovirus e serotype 4 strain cl-68578 antigen
Accession Number
DB14409
Type
Biotech
Groups
Approved
Biologic Classification
Vaccines
Other vaccines
Description

Human adenovirus e serotype 4 strain cl-68578 antigen is a vaccine.

Synonyms
  • Adenovirus Type 4 Strain Cl-68578
  • Adenovirus Type 4 Vaccine Live
  • Adenovirus Vaccine, Live, Oral, Type 4
  • Human Adenovirus E Serotype 4 Strain Cl-68578
  • Human Adenovirus Serotype 4 Strain Cl-68578
  • Human Adenovirus Serotype 4 Vaccine Strain Cl-68578
  • Mastadenovirus Human Adenovirus B Type 4 Strain Cl-68578
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Adenovirus Type 4 and Type 7 Vaccine, LiveHuman adenovirus e serotype 4 strain cl-68578 antigen (32000 [TCID_50]/1) + Adenovirus type 7 vaccine live (32000 [TCID_50]/1)OralTeva Women's Health, Inc.2011-09-16Not applicableUs
Categories
UNII
FKD3DUK39I
CAS number
Not Available

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
2-MethoxyethanolThe risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin AThe risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
AbacavirThe therapeutic efficacy of Human adenovirus e serotype 4 strain cl-68578 antigen can be decreased when used in combination with Abacavir.
AbataceptThe risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Abatacept.
AbetimusThe risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Abetimus.
ActeosideThe risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Acteoside.
AcyclovirThe therapeutic efficacy of Human adenovirus e serotype 4 strain cl-68578 antigen can be decreased when used in combination with Acyclovir.
AdafosbuvirThe therapeutic efficacy of Human adenovirus e serotype 4 strain cl-68578 antigen can be decreased when used in combination with Adafosbuvir.
AdalimumabThe risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Adalimumab.
AdefovirThe therapeutic efficacy of Human adenovirus e serotype 4 strain cl-68578 antigen can be decreased when used in combination with Adefovir.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
RxNav
1099933

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on July 05, 2018 12:02 / Updated on March 01, 2020 21:49

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates